Journals / Cukurova Medical Journal / 2021 / Cilt: 46 - Sayı: 3

Can biomarkers indicate the severity of coronary artery disease?

Biyobelirteçler, koroner arter hastalığının şiddetini gösterebilir mi?

Pages
883–888
Publication Date
2021-09-30
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

There was no significant difference in the PCT measurements between the two groups Conclusion: When Hs-TnT and Hs-CRP are evaluated together in patients with STEMI with a high SS, it may be predictive in early determining the severity of coronary artery disease.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: Biomarkers are useful measures assisting the diagnosis, treatment, and prognosis of cardiovascular diseases.
📊
Key Findings & Data:Materials and Methods: The study included a total of 166 patients that presented with ST-elevation myocardial infarction (STEMI) in the first three hours of symptom onset and underwent coronary angiography.
💡
Conclusion & Impact:There was no significant difference in the PCT measurements between the two groups Conclusion: When Hs-TnT and Hs-CRP are evaluated together in patients with STEMI with a high SS, it may be predictive in early determining the severity of coronary artery disease.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Biyobelirteç · miyokardial enfarktüs · syntax

Abstract

Purpose: Biomarkers are useful measures assisting the diagnosis, treatment, and prognosis of cardiovascular diseases. They can predict the severity of cardiovascular diseases, especially in acute myocardial infarction at the emergency department. We aimed to investigate the severity of cardiovascular disease using three biomarkers, namely cardiac troponins, C-reactive protein (CRP), and procalcitonin in patients with ST-elevation myocardial infarction who presented to the emergency department. Materials and Methods: The study included a total of 166 patients that presented with ST-elevation myocardial infarction (STEMI) in the first three hours of symptom onset and underwent coronary angiography. SYNTAX (SS) scores were calculated, and based on these scores, two groups were formed. High-sensitivity troponin T (Hs-TnT), high-sensitivite CRP (Hs-CRP), and procalcitonin levels were measured at the presentation. Results: Although the high sensitive troponin, Hs-CRP values were higher in the SYNTAX score>20 groups, there was no statistically significant difference between the two groups. There was no significant difference in the PCT measurements between the two groups Conclusion: When Hs-TnT and Hs-CRP are evaluated together in patients with STEMI with a high SS, it may be predictive in early determining the severity of coronary artery disease.

Özet

Amaç: Biyobelirteçler kardiyovasküler hastalıkların teşhisi, tedavisi ve prognozunu tayin etmede önemlidir. Acil serviste özellikle akut miyokard enfarktüsünde kardiyovasküler hastalıkların ciddiyetini tahmin edebilirler. Bu çalışmada acil servise başvuran ST elevasyonlu miyokard enfarktüsü tanısı olan hastalarda kardiyovasküler hastalıkların şiddetini kardiyak troponinler, C-reaktif protein (CRP) ve prokalsitonin olmak üzere üç biyobelirteç kullanarak araştırmayı amaçladık. Gereç ve Yöntem: Çalışmaya ST elevasyonlu miyokard enfarktüsü tanısı alan semptomlarının ilk 3 saati içerisinde başvuran ve koroner anjiografi yapılan 166 hasta alındı. SYNTAX (SS) skoruna göre hastalar iki gruba ayrıldı. Başvuru sırasında ölçülen Hs-troponin T, Hs-CRP ve prokalsitonin düzeyleri ölçüldü. Bulgular: SYNTAX skoru 20 nin üstünde olan grupta Hs-troponin ve Hs-CRP düzeyleri yüksek olmasına rağmen iki grup arasında istatistiksel olarak anlamlı fark saptanmadı. İki grup arasında prokalsitonin düzeyleri açısından istatistiksel olarak anlamlı fark saptanmadı. Sonuç: SYNTAX skoru yüksek olan ST elevasyonlu miyokard enfarktüs geçiren hastalarda Hs-troponin T ve Hs-CRP birlikte değerlendirildiğinde, erken dönemde koroner arter hastalığının şiddetini belirlemede öngörücü olabilir.

🔖

Cite This Article

KARABULUT, D., ERDAL, G. Ş., KARABULUT, U., IŞIKSAÇAN, N., SATILMIŞOĞLU, M. H., KASAPOĞLU, P., TURHAN, N. (2021). Can biomarkers indicate the severity of coronary artery disease?. Cukurova Medical Journal, Cilt: 46 - Sayı: 3, 883–888. https://ajindex.com/articles/420773

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. The global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet. 2006;367:1747-57
  2. Canto JG, Shlipak MG, Rogers WJ, Malmgren JA, Frederick PD, Lambrew CT et al. Prevalence, clinical characteristics, and mortality among patients with myocardial infarction presenting without chest pain. JAMA. 2000;283:3223-9
  3. Hamm CW, Braunwald E. A classification of unstable angina revisited. Circulation. 2000;102:118-22
  4. Tricoci P, Leonardi S, White J, White HD, Armstrong PW, Montalescot G et al. Cardiac troponin after percutaneous coronary intervention and 1-year mortality in non-ST-segment elevation acute coronary syndrome using systematic evaluation of biomarker trends. J Am Coll Cardiol. 2013;62:242-251
  5. Boden H, Ahmed TA, Velders MA, van der Hoeven BL, Hoogslag GE, Bootsma M et al. Peak and fixedtime high-sensitive troponin for prediction of infarct size, impaired left ventricular function, and adverse outcomes in patients with first ST-segment elevation myocardial infarction receiving percutaneous coronary intervention. Am J Cardiol. 2013;111:1387- 93
  6. Byrne RA, Ndrepepa G, Braun S, Tiroch K, Mehilli J, Schulz S et al. Peak cardiac troponin-T level, scintigraphic myocardial infarct size and one-year prognosis in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. Am J Cardiol. 2010;106:1212-7 7. Head SJ, Farooq V, Serruys PW, Kappetein AP. The SYNTAX score and its clinical implications. Heart. 2014;100:169-77
  7. Sianos G, Morel MA, Kappetein AP, Morice MC, Colombo A, Dawkins K et al. The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention. 2005;1:219-27
  8. Girasis C, Garg S, Räber L, Sarno G, Morel MA, Garcia-Garcia HM et al. SYNTAX score and Clinical SYNTAX score as predictors of very long-term clinical outcomes in patients undergoing percutaneous coronary interventions: a substudy of SIRolimuseluting stent compared with pacliTAXel-eluting stent for coronary revascularization (SIRTAX) trial. Eur Heart J. 2011;32:3115-27
  9. Palmerini T, Genereux P, Caixeta A, Cristea E, Lansky A, Mehran R et al. Prognostic value of the SYNTAX score in patients with acute coronary syndromes undergoing percutaneous coronary intervention: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage StrategY) trial. J Am Coll Cardiol. 2011;57:238